Leukemia Patents (Class 514/19.6)
-
Publication number: 20140315812Abstract: Provided herein is an amorphous form of a pharmaceutically acceptable salt of ezatiostat, for example, ezatiostat hydrochloride, compositions, uses and methods of preparation thereof.Type: ApplicationFiled: November 30, 2012Publication date: October 23, 2014Inventor: Steven R. Schow
-
Publication number: 20140309174Abstract: The present invention provides compounds having formula (I): and additionally provides methods for the synthesis thereof and methods for the use thereof in the treatment of cancer, wherein R1-R7, X1, X2, R, Q, and n are as defined herein.Type: ApplicationFiled: November 12, 2013Publication date: October 16, 2014Applicant: Eisai Co., LtdInventors: James J. Kowalczyk, Galina Kuznetsov, Shawn Schiller, Boris M. Seletsky, Mark Spyvee, Hu Yang
-
Patent number: 8859502Abstract: Provided are methods for treating MLL-rearranged ALL by administering to a patient an HDAC inhibitor alone or in combination with a DNA demethylating agent. Also provided are methods of treating MLL-rearranged infant ALL. Methods of treating cells by these agents are also provided. Additionally, disclosed is a method for screening for compounds capable to treat MLL-rearranged ALL, in particular, MLL-rearranged infant ALL. In one embodiment, the HDAC inhibitor is romidepsin.Type: GrantFiled: September 9, 2011Date of Patent: October 14, 2014Assignee: Celgene CorporationInventors: Ronald Stam, Dominique J. P. M. Stumpel
-
Publication number: 20140302059Abstract: In alternative embodiments, the invention provides compositions and methods for inhibiting or ablating cancer stem cells. In alternative embodiments, the invention provides compositions and methods for inhibiting the action of double-stranded RNA-specific adenosine deaminases, or ADAR, enzymes. In alternative embodiments, the invention provides compositions and methods for treating, ameliorating or preventing diseases and conditions responsive to the inhibition of cell differentiation and/or self-renewal of dysfunctional cells, cancer cells, leukemia cells, hematopoietic stem cells or cancer stem cells, e.g., leukemia or Chronic Myeloid Leukemia (CML). In alternative embodiments, the invention provides compositions and methods for inhibiting a Sonic Hedgehog (Shh) pathway, e.g., by using a Smoothened (SMO) protein inhibitor.Type: ApplicationFiled: September 7, 2012Publication date: October 9, 2014Inventors: Catriona H. Jamieson, Qingfei Jiang, Kelly A. Frazer, Christian L. Barrett, Anil Sadarangani, Alice Shih, Angela Court, Leslie Crews Robertson
-
Publication number: 20140303080Abstract: N-acyldipeptide derivatives are described. Compositions comprising the N-acyldipeptide derivatives are therapeutically effective for topical or systemic administration to alleviate or improve conditions, disorders, diseases, symptoms or syndromes associated with a tumor, cancer, immune, nervous, vascular, musculoskeletal or cutaneous system, or other tissue or system in a subject.Type: ApplicationFiled: October 31, 2012Publication date: October 9, 2014Inventors: Ruey J. Yu, Eugene J. Van Scott
-
Publication number: 20140294851Abstract: Base-labile crosslinkers, base-labile conjugates comprising such crosslinkers, methods of their synthesis and use are disclosed.Type: ApplicationFiled: April 1, 2013Publication date: October 2, 2014Inventor: MARK QUANG NGUYEN
-
Publication number: 20140296139Abstract: MOTS3 is a novel polypeptide. Methods of treating diseases such as diabetes, obesity, fatty liver, and cancer using MOTS3 and pharmaceutical compositions thereof are disclosed herein.Type: ApplicationFiled: March 14, 2014Publication date: October 2, 2014Inventors: Pinchas COHEN, Changhan LEE, Laura J. COBB
-
Publication number: 20140294865Abstract: The invention relates to tumor therapy. In one aspect, the present invention relates to conjugates of an amatoxin and a target-binding moiety, e.g. an antibody, connected by certain linkages, which are useful in the treatment of cancer. In a further aspect the invention relates to pharmaceutical compositions comprising such conjugates.Type: ApplicationFiled: March 9, 2012Publication date: October 2, 2014Applicant: HEIDELBERG PHARMA GMBHInventors: Werner Simon, Christian Lutz, Christoph Muller, Jan Anderl
-
Publication number: 20140271652Abstract: Disclosed are immunomodulatory polypeptides that elicit an unusual induced cytokine profile, compositions comprising such polypeptides, compositions comprising antibodies that specifically bind to such polypeptides, and methods of using the same, including in cancer treatment, in the treatment of autoimmune diseases, in organ transplantation and for reducing graft rejection, for promoting fertility, and for identifying a neutrophil subset and/or other cellular subset including by flow cytometry. Pharmaceutical compositions and kits, and treatment methods are also disclosed.Type: ApplicationFiled: March 12, 2014Publication date: September 18, 2014Applicant: Institute of Arthritis Research, LLCInventor: Craig D. Scoville
-
Publication number: 20140271488Abstract: Synthesis of compounds having varying degrees of conformational rigidity is obtained via a low cost, high yield and efficient synthetic reactions. The library of compounds is structurally diverse having at least one or more chiral centers and providing large numbers of compounds having building block diversity and substantial scaffold diversity. The compounds further provide a novel method for obtaining candidate therapeutic agents for prevention, treatment or diagnosis of diseases.Type: ApplicationFiled: September 7, 2012Publication date: September 18, 2014Applicant: The Scripps Research InstituteInventors: Glenn C. Micalizio, Thomas Kodadek, Mohosin Sarkar
-
Patent number: 8834876Abstract: An inducing agent or enhancing agent, for the expression of HM1.24 antigen in hematopoietic tumor cells, comprising interferon ?, interferon ?, or the IRF-2 protein as an active ingredient, as well as an antitumor agent for hematopoietic tumors which comprises a combination of said inducing agent or enhancing agent and an antibody against HM1.24.Type: GrantFiled: April 13, 2011Date of Patent: September 16, 2014Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Masaaki Kosaka, Shuji Ozaki, Yuji Wakahara
-
Publication number: 20140243276Abstract: A method of using a Smac mimetic and pharmaceutical compositions thereof.Type: ApplicationFiled: September 27, 2012Publication date: August 28, 2014Applicant: TETRALOGIC PHARMACEUTICALS CORPORATIONInventors: David Weng, Srinivas Chunduru, Martin Graham
-
Publication number: 20140228290Abstract: The invention provides compositions and methods to treat cancer with an agent that increases reactive oxygen species (ROS) levels in cancer cell mitochondria (“an XTPP agent”) or a pharmaceutically acceptable salt thereof, an inhibitor of hydroperoxide metabolism and a pharmaceutically acceptable diluent or carrier.Type: ApplicationFiled: August 2, 2012Publication date: August 14, 2014Applicants: REGENTS OF THE UNIVERSITY OF MICHIGAN, UNIVERSITY OF IOWA RESEARCH FOUNDATIONInventors: Douglas R. Spitz, Michael K. Schultz, Kyle Kloepping, Yueming Zhu, Nukhet Aykin-Burns, Max S. Wicha
-
Patent number: 8791076Abstract: The invention relates to compounds of Formula I: and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, and R3 are defined as set forth in the specification. The compounds are agonists of neurotrophin (such as nerve growth factor) receptors.Type: GrantFiled: August 31, 2011Date of Patent: July 29, 2014Inventors: Pablo Villoslada, Angel Messeguer
-
Publication number: 20140206624Abstract: Compositions and methods for the treatment of leukemia by inhibiting FOXO signaling are described.Type: ApplicationFiled: February 6, 2012Publication date: July 24, 2014Applicants: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., THE GENERAL HOSPITAL CORPORATIONInventors: Stephen Matthew Sykes, David T. Scadden, Dwight Gary Gilliland
-
Publication number: 20140206622Abstract: It is provided PACE4 inhibitors and their uses for treating infection, cancer. Particularly, it is provided a method or use for the treatment of a cancer in a subject, comprising administering to the subject a therapeutically effective amount of the PACE4 inhibitors or the composition disclosed.Type: ApplicationFiled: August 30, 2012Publication date: July 24, 2014Applicant: SOCPRA SCIENCES SANTE ET HUMAINES S.E.C.Inventors: Robert Day, Witold A. Neugebauer, Yves Dory
-
Publication number: 20140199332Abstract: Disclosed are: a peptide comprising an amino acid sequence composed of contiguous nine amino acid residues derived from a WT1 protein, wherein an amino acid residue at position 2 in the amino acid sequence is selected from the group consisting of Ala, Ile, Leu, Val, Phe, Tyr, Ser and Asp and an amino acid residue at position 9 in the amino acid sequence is Arg; a polynucleotide encoding the peptide; a pharmaceutical composition comprising the peptide; and a method of treating cancer using the peptide.Type: ApplicationFiled: December 31, 2013Publication date: July 17, 2014Applicant: International Institute of Cancer Immunology, Inc.Inventor: Haruo SUGIYAMA
-
Patent number: 8778350Abstract: Disclosed are: a peptide comprising an amino acid sequence composed of contiguous nine amino acid residues derived from a WT1 protein, wherein an amino acid residue at position 2 in the amino acid sequence is selected from the group consisting of Ala, Ile, Leu, Val, Phe, Tyr, Ser and Asp and an amino acid residue at position 9 in the amino acid sequence is Arg; a polynucleotide encoding the peptide; a pharmaceutical composition comprising the peptide; and others.Type: GrantFiled: March 2, 2012Date of Patent: July 15, 2014Assignee: International Institute of Cancer Immunology, Inc.Inventor: Haruo Sugiyama
-
Publication number: 20140193333Abstract: The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of acute myeloid leukemia (AML), B-cell chronic lymphocytic leukemia, breast cancer, colorectal cancer, kidney cancer, head and neck cancer, lung cancer, ovarian cancer or pancreatic cancer, for monitoring the effectiveness of acute myeloid leukemia (AML), B-cell chronic lymphocytic leukemia, breast cancer, colorectal cancer, kidney cancer, head and neck cancer, lung cancer, ovarian cancer or pancreatic cancer treatment, and for drug development. The present invention also provides methods and compositions for depletion of immune cells to treat inflammatory diseases.Type: ApplicationFiled: June 28, 2012Publication date: July 10, 2014Applicant: OXFORD BIOTHERAPEUTICS LTDInventors: Christian Rohlff, Alasdair Stamps
-
Patent number: 8754045Abstract: Compositions and methods are provided to destroy internal cancerous lesions selectively by the administration of a combination of a debridement protease enzyme and a denaturant of cell structural proteins and or cell adhesion proteins.Type: GrantFiled: May 14, 2007Date of Patent: June 17, 2014Inventor: James A. Livingston
-
Patent number: 8748388Abstract: Antitumoral compounds of Formula I, and pharmaceutically acceptable salts, derivatives, tautomers, prodrugs or stereoisomers thereof useful as antitumour agents.Type: GrantFiled: December 10, 2008Date of Patent: June 10, 2014Assignee: Pharma Mar, S.A.Inventors: Judit Tulla-Puche, Eleonora Marcucci, Núria Bayó-Puxan, Fernando Albericio, Maria del Carmen Cuevas Marchante
-
Publication number: 20140147451Abstract: A method of diagnosing B-CLL in a subject in need thereof is provided. The method comprising determining in a biological sample of the subject a level of CD84 isoform C (SEQ ID NO: 30), wherein an increase in the level of the CD84 isoform C (SEQ ID NO: 30) beyond a predetermined threshold with respect to a level of the CD84 in a biological sample from a healthy individual is indicative of the B-CLL.Type: ApplicationFiled: February 5, 2014Publication date: May 29, 2014Applicant: Yeda Research and Development Co. Ltd.Inventors: Idit SHACHAR, Inbal Binsky, Mirko Sobotta
-
Publication number: 20140142045Abstract: The present invention provides the use of a peptide comprising an amino acid sequence of SEQ ID NO:3, or the encoding nucleic acid thereof, for manufacturing medicament for treatment of diseases associated with increased NF-?B activity. The peptide can interact with IKB and influence phosphorylation of IKB in the tyrosine at position 42, thereby inhibiting the signal pathway of NF-?B.Type: ApplicationFiled: April 25, 2011Publication date: May 22, 2014Applicant: Shandong Vigene Biosciences, Inc.Inventor: Wenbo Li
-
Publication number: 20140142044Abstract: Novel compounds are provided that bind to polo-like kinases through the polo-box domain. In certain embodiments, the novel compounds are PEGylated peptides. The PEGylated peptides in accordance with the invention demonstrate high PBD-binding affinity. In certain embodiments, the PEGylated peptides have also achieved activities in whole cell systems. The invention also provides compounds that bind polo-like kinases through the polo-box domain and possess reduced anionic charge. Further provided are methods of design and/or synthesis of the PEGylated peptides and methods of use thereof. The invention provides methods of use of the compounds and methods of synthesis of the compounds. The compounds of the invention have potential therapeutic activity in view of their binding and inhibitory activities towards Plk1. They are based on the amino acid sequence PLHSpT (phosphorylated Thr). The PEG moiety, when present, is covalently attached at the N-terminus.Type: ApplicationFiled: April 12, 2012Publication date: May 22, 2014Applicant: The United States of America, as represented by the Secretary, Department of Health & Human ServicInventors: Terrence R. Burke, JR., Wenjian Qian, Fa Liu, Kyung S. Lee, Jung-Eun Park
-
Patent number: 8716233Abstract: The present invention is based upon the identification of regions within the NOTCH-1 receptor that, when mutated, lead to increase receptor signaling. The mutations are associated with uncontrolled cellular growth and this growth may be arrested using agents that interfere with NOTCH-1 activity, such as inhibitors of gamma-secretase. Assays for the NOTCH-1 mutations may be used diagnostically or as part of a treatment regimen for cancer patients.Type: GrantFiled: May 22, 2009Date of Patent: May 6, 2014Assignees: The Brigham and Women's Hospital, Inc., Dana-Farber Cancer Institute, Inc.Inventors: Jon C. Aster, Stephen C. Blacklow, A. Thomas Look, Adolfo A. Ferrando, Andrew P. Weng
-
Patent number: 8709998Abstract: The invention features targeted cytotoxic compounds and methods relating to their therapeutic use for the treatment of neoplasia and other conditions.Type: GrantFiled: April 21, 2004Date of Patent: April 29, 2014Assignee: Ipsen Pharma S.A.S.Inventors: Zheng Xin Dong, Yeelena Shen, Jeanne Mary Comstock, Sun H. Kim
-
Patent number: 8709418Abstract: According to the present invention, a cancer antigen protein to be specifically expressed on the surfaces of cancer cells is identified and thus the use of an antibody targeting the cancer antigen protein as an agent for treating and/or preventing a cancer is provided. Specifically, the present invention provides a pharmaceutical composition for treating and/or preventing a cancer, which comprises an antibody comprising a heavy chain variable region that comprises SEQ ID NOS: 39, 40, and 41 and a light chain variable region that comprises SEQ ID NOS: 43, 44, and 45 or a fragment thereof as an active ingredient and having immunological reactivity with a CAPRIN-1 protein.Type: GrantFiled: February 4, 2011Date of Patent: April 29, 2014Assignee: Toray Industries, Inc.Inventors: Fumiyoshi Okano, Takanori Saito
-
Publication number: 20140113855Abstract: This disclosure features modified release pharmaceutical formulations (e.g., extended release pharmaceutical formulations; e.g., solid dosage forms, e.g., tablets) that are useful for the oral administration of oprozomib, or a pharmaceutically acceptable salt thereof, to a human or animal subject as well as methods of making and using the formulations.Type: ApplicationFiled: October 24, 2013Publication date: April 24, 2014Inventors: Mouhannad Jumaa, Tony Muchamuel, Naveen Bejugam, Hansen Wong, Christopher J. Kirk, Rahul Vishram Manek, Sanjeev Sharma
-
Publication number: 20140086903Abstract: The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B-cell related autoimmune, inflammatory, or hyperproliferative diseases.Type: ApplicationFiled: March 15, 2013Publication date: March 27, 2014Inventors: Philip TAN, Charles G. Cerveny, Sandy A. Simon, Anne Nilsson, William Brady, Peter A. Thompson, Cecile Morales
-
Publication number: 20140088023Abstract: The present invention provides materials and methods useful to treat various sGC?1-expressing cancers. Materials include peptides which interfere with sGC?1's pro-survival functions, thereby resulting in apoptosis of sGC?1-expressing cells. In addition, the present invention provides screening assays, diagnostic assays, methods to prognose, methods to treat, and kits.Type: ApplicationFiled: November 1, 2013Publication date: March 27, 2014Applicant: THE UNIVERSITY OF TOLEDOInventors: Lirim Shemshedini, Shao-Yong Chen, Changmeng Cai, Chen-Lin Hsieh
-
Publication number: 20140080753Abstract: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.Type: ApplicationFiled: November 12, 2013Publication date: March 20, 2014Applicant: Onyx Therapeutics, Inc.Inventors: Kevin D. SHENK, Francesco PARLATI, Han-jie ZHOU, Catherine SYLVAIN, Mark S. SMYTH, Mark K. BENNETT, Guy J. LAIDIG
-
Publication number: 20140073586Abstract: A composition comprising leukotoxin proteins isolated from a bacterium is provided. In this composition, greater than 85% of the leukotoxin proteins are chemically modified at a basic amino acid residue, and the proteins induce cell death in myeloid leukocytes, while remaining substantially non-toxic to lymphoid leukocytes, lymphocytes, and red blood cells. Also provided is a method of selectively inducing cell death in myeloid leukocytes. The method comprises contacting the myeloid leukocytes with a composition comprising leukotoxin proteins. These leukotoxin proteins may be isolated from the NJ4500 strain of Actinobacillus actinomycetemcomitans. A method of purifying leukotoxin protein from the NJ4500 strain of Actinobacillus actinomycetemcomitans is also provided, as well as an assay that allows for the rapid determination of the activity of a given drug against leukemic cells either taken from a patient or derived from a cell line. The assay is performed in the presence of whole blood or serum.Type: ApplicationFiled: September 11, 2013Publication date: March 13, 2014Applicant: Rutgers, The State University of New JerseyInventor: Scott Charles Kachlany
-
Publication number: 20140073585Abstract: Two vIRF4 (Kaposi's-sarcoma-associated-herpesvirus vIRF4) peptides, vif1, corresponding to aa202-216 of vIRF4, and vif2, corresponding to aa220-236 of vIRF4, are potent and selective HAUSP antagonists. The vif1 and vif2 peptides robustly suppress HAUSP DUB enzymatic activity, ultimately leading to p53-mediated anti-cancer activity. The vif1 and vif2 peptides, along with their homologues, are useful in treating ALL.Type: ApplicationFiled: August 20, 2013Publication date: March 13, 2014Applicant: UNIVERSITY OF SOUTHERN CALIFORNIAInventor: Jae Jung
-
Publication number: 20140066386Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administration of a compound of formula A, wherein R is H, halo, or C1-C6 alkyl; R? is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient.Type: ApplicationFiled: February 7, 2013Publication date: March 6, 2014Applicant: GILEAD CALISTOGA LLCInventor: Gilead Calistoga LLC
-
Publication number: 20140056906Abstract: The invention provides human secreted proteins (SECP) and polynucleotides which identify and encode SECP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of SECP.Type: ApplicationFiled: October 8, 2013Publication date: February 27, 2014Applicant: INCYTE CORPORATIONInventors: Henry Yue, Monique G. Yao, Ameena R. Gandhi, Mariah R. Baughn, Anita Swarnakar, Narinder Walia, Madhusudan M. Sanjanwala, Michael Thorton, Vicki S. Elliott, Yan Lu, Kimberly J. Gietzen, Neil Burford, Li Ding, April J. A. Hafalia, Y. Tom Tang, Olga Bandman, Bridget A. Warren, Cynthia D. Honchell, Dyung Aina M. Lu, Kavitha Thangaveln, Sally Lee, Yuming Xu, Junming Yang, Preeti G. Lal, Bao Tran, Craig H. Ison, Brendan M. Duggan, Stephanie Sapperstein
-
Publication number: 20140057833Abstract: Short peptide mimetics of adiponectin suitable for development as pharmaceutical agonists in the treatment of cellular proliferative disorders such as cancer and atherosclerosis are provided.Type: ApplicationFiled: April 11, 2012Publication date: February 27, 2014Applicant: TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: Laszlo Otvos, Eva Surmacz
-
Publication number: 20140056910Abstract: Provided are a pharmaceutical composition which enhances the sensitivity of a cancer to a molecular target drug, such as gefitinib and erlotinib, wherein the cancer has resistance to the molecular target drug, and a cancer therapeutic agent effective against a cancer having resistance to a molecular target drug, such as gefitinib and erlotinib. The pharmaceutical composition comprising an HGF-MET receptor pathway inhibitor enhances the sensitivity of a cancer to a molecular target drug, such as gefitinib and erlotinib, even though the cancer has resistance to the molecular target drug. The cancer therapeutic agent comprising a molecular target drug in combination with an HGF-MET receptor pathway inhibitor is effective against a cancer having resistance to the molecular target drug.Type: ApplicationFiled: October 18, 2013Publication date: February 27, 2014Applicant: Kringle Pharma Inc.Inventors: Seiji YANO, Kunio MATSUMOTO
-
Publication number: 20140051643Abstract: The present invention thus provides microbial products as anticancer agents and pharmaceutical compositions comprising isolated and purified proteins or synthetic peptides, and methods of using them for the treatment of cancer. It is very important to develop new anticancer bioactive peptides having high activity and low toxicity; given that most currently available anticancer therapies either have significant toxicity, and/or are prone to development of resistance.Type: ApplicationFiled: September 30, 2011Publication date: February 20, 2014Inventors: Anil Suri, Deepika Kanojia, Prabhakar Salunkhe, Sidharth Mahali, Sunil Kumar Manna, Avadhesha Surolia, Ananda Chakrabarty
-
Patent number: 8653031Abstract: We describe preparation of compounds of an AT1 receptor antagonist(s) and Angiotensin (1-7), for example, Angiotensin-(1-7) losartanate and analogues thereof, and/or mixtures of these systems, pharmaceutical compositions thereof and use of their derivative products. Cyclodextrins and derivatives thereof may be used for the micro-encapsulation of compounds, for example, Angiotensin (1-7) losartanate, liposomes and biodegradable polymers and/or mixtures of these systems and/or derivative products for the obtainment of nano- or microparticles as controlled or sustained release devices of Ang-(1-7) losartanate and analogues and/or mixtures thereof. The compounds may be used as agents for treating or preventing hypertension, cardiovascular diseases, heart hypertrophy, heart failure, coronary diseases, such as angina pectoris, endothelial disorder or endothelial lesions, as a consequence, for example, of atherosclerosis processes or in association with diabetes mellitus.Type: GrantFiled: October 30, 2006Date of Patent: February 18, 2014Assignee: Universidade Federal de Minas GeraisInventors: Rubén Dario Sinisterra Millán, Cynthia Fernades Ferreira Santos, Robson Augusto Souza Dos Santos, Ivana Silva Lula, Frederico Barros De Sousa, Pedro Pires Goulart Guimaraes, Angelo Márcio Leite Denadai
-
Publication number: 20140037634Abstract: The present invention relates to novel regulatory T cell proteins. One protein, designated PD-L3, resembles members of the PD-L1 family, and co-stimulates ?CD3 proliferation of T cells in vitro. A second, TNF-like, protein has also been identified as being upregulated upon ?CD3/?GITR stimulation. This protein has been designated Treg-sTNF. Proteins, antibodies, activated T cells and methods for using the same are disclosed. In particular methods of using these proteins and compounds, preferably antibodies, which bind or modulate (agonize or antagonize) the activity of these proteins, as immune modulators and for the treatment of cancer, autoimmune disease, allergy, infection and inflammatory conditions, e.g.Type: ApplicationFiled: May 24, 2013Publication date: February 6, 2014Inventors: Randolph J. Noelle, Li Wang
-
Patent number: 8642580Abstract: Compounds which are ?-halogenoacryloyl distamycin derivatives of formula (I) wherein R1 is a bromine or chlorine atom; R2 is a distamycin or distamycin-like framework as set forth in the specification; or a pharmaceutically acceptable salt thereof; are cytotoxic agents particularly effective in the treatment of tumors over expressing GSH/GSTs system and which are poorly responsive or even resistant to conventional antitumor therapies.Type: GrantFiled: June 20, 2001Date of Patent: February 4, 2014Assignee: Nerviano Medical Sciences S.R.L.Inventors: M. Cristina Geroni, Paolo Cozzi, Italo Beria
-
Publication number: 20140023642Abstract: Disclosed are 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones thereof, represented by the Formula (I) wherein Ar, R1-R6 are defined herein. Compounds having Formula (I) are PARP inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of PARP activity.Type: ApplicationFiled: March 31, 2012Publication date: January 23, 2014Applicant: Impact Therapeutics, Inc.Inventors: Sui Xiong Cai, Ye Edward Tian, Haijun Dong, Qingbing Xu, Lizhen Wu, Lijun Liu, Yangzhen Jiang, Qingli Bao, Guoxiang Wang, Feng Yin, Chengyun Gu, Xiuhua Hu, Xiaozhu Wang, Sishun Kang, Shengzhi Chen
-
Patent number: 8633161Abstract: The invention provides for methods of treating a mammal who has a BCR/ABL-mediated leukemia, including chronic myelogenous leukemia (CML), particularly the blast crisis stage of CML, Philadelphia-positive acute lymphoblastic leukemia (Ph?-ALL), and refractory leukemias. The invention also provides for compounds for the treatment of these leukemias and methods of identifying anti-leukemic agents.Type: GrantFiled: March 24, 2006Date of Patent: January 21, 2014Assignee: The Ohio State University Research FoundationInventors: Danilo Perrotti, Paolo Neviani, Ramasamy Santhanam, John C. Byrd, Guido Marcucci, Natarajan Muthusamy, Ching-Shih Chen
-
Patent number: 8633154Abstract: The present invention is directed to cyclodepsipeptide compounds having antineoplastic and/or antimicrobial activity, preferably Kitastatin 1. The present invention is further directed to methods of inhibiting cancer cell growth and/or microbial growth in a host inflicted therewith by administering cyclodepsipeptide compounds to the inflicted host.Type: GrantFiled: March 6, 2013Date of Patent: January 21, 2014Assignee: Arizona Board of Regents, a body corporate of the State of Arizona Acting for and on behalf of Arizona State UniversityInventors: George R. Pettit, Rui Tan, Robin K. Pettit
-
Publication number: 20130331310Abstract: This invention describes an ICE inhibitor prodrug (I) having good bioavailability. Compound I is useful for treating IL-1 mediated diseases such as rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, inflammatory peritonitis, septic shock, pancreatitis, traumatic brain injury, organ transplant rejection, osteoarthritis, asthma, psoriasis, Alzheimer's disease, myocardial infarction, congestive heart failure, Huntington's disease, atherosclerosis, atopic dermatitis, leukemias and related disorders, myelodysplastic syndrome, uveitis or multiple myeloma.Type: ApplicationFiled: December 10, 2012Publication date: December 12, 2013Inventor: Vertex Pharmaceuticals Incorporated
-
Patent number: 8598127Abstract: Disclosed are peptides for inhibiting mdm2 (mouse double minute 2) and a pharmaceutical composition comprising the same.Type: GrantFiled: December 29, 2004Date of Patent: December 3, 2013Assignee: Korea Research Institute of Bioscience & BiotechnologyInventors: Kyou-Hoon Han, Seung-Wook Chi, Hyun-Jeong Kim, Si-Hyung Lee, Min-Jung Ahn, Do-Hyoung Kim, Jae-Sung Kim, Shin-Ae Park
-
Patent number: 8586543Abstract: The present application includes methods for using IL-8 as a biomarker for, e.g., tumor size, for example, during course of treatment with an anti-cancer agent such as an ERK inhibitor.Type: GrantFiled: August 17, 2009Date of Patent: November 19, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Ahmed A. Samatar, Brian Long, Priya Dayananth, Diane Levitan, Marsha Smith
-
Patent number: 8580743Abstract: A recombinant galectin 9 (rGal 9) is provided which exhibits an immune system-mediated action and a direct action on tumor cells (i.e., activity of inducing the intercellular adhesion and apoptosis of the tumor cells), thereby potent in inducing the inhibition of cancer metastasis and reduction. Moreover, the rGal 9 exerts no efficacy on non-activated lymphocytes but can induce apoptosis in activated T cells, in particular, CD4-positive T cells causing an excessive immune response.Type: GrantFiled: August 22, 2012Date of Patent: November 12, 2013Assignee: Galpharma Co., Ltd.Inventors: Nozomu Nishi, Mitsuomi Hirashima, Akira Yamauchi, Aiko Ito
-
Publication number: 20130288984Abstract: The present invention relates to a method of treating cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering a proteasome inhibiting compound, and N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide, or a pharmaceutically acceptable salt thereof, and optional additional antineoplastic agents, to a human in need thereof.Type: ApplicationFiled: January 11, 2012Publication date: October 31, 2013Applicant: GLAXOSMITHKLINE LLCInventor: Rakesh Kumar
-
Publication number: 20130273151Abstract: Described herein is a pharmaceutical composition for treating a subject having a cancer and/or myeloproliferative disorder associated with overexpression of a HOXA1 gene product where an effective amount of at least one miR-10a gene product or an isolated variant or biologically-active fragment thereof is administered to the subject sufficient to decrease expression of the HOXA1 gene product in the subject.Type: ApplicationFiled: June 25, 2013Publication date: October 17, 2013Inventors: Carlo M. Croce, Ramiro Garzon, George A. Calin